StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX)

Investment analysts at StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research report issued on Monday. The brokerage set a “sell” rating on the stock.

Separately, Maxim Group lowered Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th.

Moleculin Biotech Stock Up 71.7 %

NASDAQ MBRX opened at $2.18 on Monday. Moleculin Biotech has a 52-week low of $0.40 and a 52-week high of $10.35. The company has a fifty day moving average of $1.68 and a 200-day moving average of $2.22.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.